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appears to be an independent risk factor for the failure to attain BP and dual BP 
and LDL-C goals in patients with concomitant hypertension and dyslipidemia. 
These findings suggest that future research is needed to determine the 
underlying link between obesity and failure to attain these goals.  
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BACKGROUND: Past literature recommends varied combinations of 2 or more 
anti-hypertensive drugs as polypill therapy for Myocardial Infarction (MI). 
OBJECTIVES: This study examined the utilization pattern and predictors of the 
most combinations for MI patients. METHODS: Data from 2009 Medical 
Expenditure Panel Survey (MEPS) was employed to examine the use of anti-
hypertensive drug combinations among MI patients, defined by ICD-9-CM code 
‘410’. Using MEPS sampling weights, descriptive analysis and survey logistic were 
used to evaluate prevalence and predictors of utilizing 2 or more anti-
hypertensive drug combinations among MI patients. RESULTS: An estimated 
5.91million patients (1.93%, 95%CI: 1.70%-2.15%) were diagnosed with MI in 2009. 
Of these, 5.03 million patients (85.92%, 95%CI: 82.62%-89.22%) were using at least 
one anti-hypertensive and 3.60million patients (60.87%, 95%CI: 56.19%-65.55%) 
were using a combination of ≥2 anti-hypertensives. Most frequently utilized 
combination of ≥2 anti-hypertensives was of Angiotensin inhibitors or 
Angiotensin receptor blockers (ACEARB) and Beta-blockers (BBS) with a 
prevalence of 2.41million patients (40.86%, 95%CI: 36.35%-45.36%). Multivariate 
analysis revealed Hypertension (OR 2.43: 1.49 – 3.96), Congestive Heart Failure or 
CHF (OR 3.05: 1.33 – 7.00), and Chronic Atherosclerosis (OR 2.08: 1.32 – 3.29) as its 
statistically significant predictors of two or more hypertensive combinations. 
The most prevalent combination of ≥3 anti-hypertensives was for a combination 
of ACEARB, BBs and Diuretics with a prevalence of 1.19 million (20.11%, 95%CI: 
16.52%-23.70%). The significant predictors of utilizing this combination were 
Presence of any limitation (OR 3.47: 1.69 – 7.13), Hypertension (OR 2.22: 1.08 – 
4.58), CHF (OR 6.10: 2.92 – 12.73), and Chronic Atherosclerosis (OR 2.03: 1.12 – 
3.70). CONCLUSIONS: Combinations of ACEARB and BBs with or without 
Diuretics were the most commonly used combinations in patients with MI. 
Comorbid hypertension, CHF and Chronic atherosclerosis were the primary 
disease-based predictors of these combinations.  
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OBJECTIVES: Customer segmentation is a strategic tool employed by the 
pharmaceutical and life sciences industries traditionally focusing on 
understanding physicians and patients. With resources and budget cuts, 
pharmaceutical companies have increasingly identified the need to successfully 
and cost-effectively prioritise and target payers by understanding their drivers, 
motivations, barriers and limitations when assessing, endorsing or restricting 
new products. Our study aimed to develop an attitudinal based, scalable payer 
segmentation model to investigate payers’ attitudes and behaviours towards the 
managed entry of novel agents in the cardiology area in the health care systems 
of countries within the EU. METHODS: A quantitative data collection and 
advanced statistical analysis methodology was employed with regional and local 
payers in eight markets to define the segmentation according to attitudes and 
beliefs relevant to the therapy area. Subsequently, in-depth semi-structured 
telephone interviews were conducted to explore the rationale behind payers’ 
views, along with perceived challenges relating to the entry of novel class of 
cardiovascular agents. RESULTS: Quantitative segmentation identified four key 
distinct segments of payers displaying unique attitudes and beliefs towards 
entry of the novel class of cardiovascular agents. The segmentation approach 
identified key differentiating factors between segments, allowing full profiling of 
each group. Payers’ underlying values were identified and expanded upon 
resulting in insight to what is important to them as individuals as well as 
decision-makers, what motivates them and what restricts them. CONCLUSIONS: 
This method of segmentation proved valuable in gaining payer insights which 
were utilized to prioritise targeting of payer segments. In addition, 
communication and messaging strategies were optimised for these payer groups. 
The findings helped inform service redesign strategies within health care 
systems to include the novel agents in the treatment guidelines and to reduce 
human and financial resources when treating the specific condition.  
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OBJECTIVES: The prompt treatment of ST segment elevation myocardial 
infarction (STEMI) is associated with conservation of cardiac function and 
reduced mortality. Acquisition of pre-hospital electrocardiogram (ECG) by first 
responders and digital transmission of the ECG to the hospital has been 
identified as a strategy to reduce time to treatment to the recommended 90 
minutes. The purpose of this study was to summarize the literature on the 
difference between patients with pre-hospital ECG to patients with in-hospital 
ECG. METHODS: This systematic review of MEDLINE indexed articles used the 
terms Dyspnea [MeSH] OR Chest Pain [MeSH] OR Myocardial Infarction/therapy 
[MAJR] with Time Factor [MeSH] and Comparative Study [pub type]. Study 
inclusions were: English, human, publication between January 1, 2002 to 
November 30, 2012. Case reports, letters, news articles and reviews were 
excluded. Comparative studies which included a group with pre-hospital ECG 
with transmission to the hospital and a control group of patients with in-
hospital ECG were eligible for inclusion. The data outcomes extracted included 
patient characteristics, onset to treatment (OTT) and door to treatment time 
(DTT). RESULTS: The search found 1029 articles, 8 passed two-tiered screening 
and were extracted. Three studies described thrombolysis, six studies described 
angioplasty (one study included both treatments). Four studies reported OTT, the 
pre-hospital ECG group had statistically significant shorter times (range 64-260 
min pre-hospital ECG and 103-432 min in-hospital ECG). Six studies reported DTT 
the pre-hospital ECG group were statistically significantly shorter (range 20-100 
min pre-hospital ECG group and 17-133 in-hospital ECG). Pre-hospital groups 
reported median DTT of <90 minutes (range 50-66 min). CONCLUSIONS: This 
review found significant beneficial differences in the onset to treatment and 
door to treatment times of STEMI patients with pre-hospital ECG. Transmission 
of pre-hospital ECG is an important component of a strategy to achieve door to 
treatment times of under 90 minutes.  
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OBJECTIVES: To determine the cost-effectiveness of Transcatheter aortic valve 
implantation (TAVI) compared to surgical aortic valve replacement (SAVR) in a 
high-risk aortic stenosis (AS) population from the perspective of the UK health 
and personal social services. METHODS: A Markov model was developed to 
enable a cost-utility analysis employing NICE reference case methods. A 
systematic review was conducted to identify model parameter values. Mean 
utility values per NYHA category were derived from a UK high-risk AS 
population. Two-year TAVI and SAVR effectiveness was taken from the PARTNER 
A trial. Costs and effects were modelled from two years over a 10 year horizon 
via NYHA health state transitions. Incremental cost-effectiveness ratios (ICER) 
and cost effectiveness acceptability curves (CEAC) were calculated and 
deterministic and probabilistic sensitivity analyses conducted. RESULTS: Despite 
greater procedural costs (£16,500 vs. £9,256), TAVI was cost-effective compared to 
SAVR over 10 years (costs £52,593 vs. £53,943 and QALYs 2.81 vs 2.75), indicating 
TAVI dominated SAVR. This appeared to be due to greater SAVR post-surgical 
costs and attendant length and cost of hospital stay. The results appeared robust 
to a number of deterministic sensitivity (including high stroke rates, worst case 
scenario complication rates, alternative utility values and higher costs) and 
probabilistic analyses. Given modest cost savings and QALY benefits conferred 
by TAVI, results were sensitive to some parameter changes when incurred by 
one arm in isolation. The CEAC indicated that at a £20,000 incremental QALY 
willingness to pay threshold, TAVI had a 64.6% likelihood of being cost-effective. 
CONCLUSIONS: This economic evaluation is the first to incorporate two year 
data comparing TAVI and SAVR in elderly high risk AS patients. TAVI is likely to 
be a cost-effective option compared to SAVR. However, uncertainty surrounding 
the long-term outcomes for TAVI patients remains; this could have a substantive 
impact on estimates of cost-effectiveness.  
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OBJECTIVES: Cigarette smoking is a major risk factor for cardiovascular disease. 
Recent research has shown that deaths due to cardiovascular problems are 
double in women who smoke. The use of smoking cessation agents is one of the 
most effective ways to quit smoking. The purpose of this study is to analyze 
trends in smoking status and utilization of smoking cessation agents in women 
with cardiovascular disease from 2001-2010. METHODS: A longitudinal 
retrospective database analysis was done to identify smokers with 
cardiovascular disease during the period from 2001 to 2010 by using Medical 
Expenditure Panel Survey (MEPS) data. Trends in smoking status and patient 
reported use of smoking cessation agents were observed to compare prevalence 
of smoking and use of cessation agents among women. RESULTS: A cohort of 
8331 smokers with cardiovascular disease was identified over a 10 year period 
which showed more female smokers than males. There was an inconsistent 
increase in the number of female smokers from 2001 to 2010 with maximum 
smokers of 54.33% in 2003. After 2003, the percentage of female smokers started 
decreasing inconsistently. Female smokers using smoking cessation agents in 
2007 were 8.51% and later there was a consistent decrease in the use of these 
agents until 2010, which reached 5.29%. The 10-year data showed that females 
were more likely to use smoking cessation agents than males. CONCLUSIONS: 
Despite the increased risk among female smokers, results indicate higher 
prevalence of smoking among women. Although the utilization of smoking 
cessation is increasing, overall proportion of users is still considerably low. There 
is a need for continued efforts to reduce smoking among women more 
aggressively. Increasing utilization of smoking cessation agents may help in 
changing current trends.  
